Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TomaGold Borehole EM Survey Confirms Berrigan Deep Zone (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Biohaven Ltd BHVN

Healthcare Biotechnology
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical... see more

Current News (NYSE:BHVN)

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

PR Newswire December 11, 2025

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

PR Newswire November 13, 2025

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

PR Newswire November 12, 2025

Biohaven Announces Proposed Public Offering of Common Shares

PR Newswire November 11, 2025

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

PR Newswire November 10, 2025

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

PR Newswire November 4, 2025

Class Action Lawsuit Filed: Biohaven Ltd. (BHVN) - Join by September 12, 2025 - Contact Levi & Korsinsky

ACCESS Newswire September 12, 2025

BHVN DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Biohaven Ltd. Investors to Secure Counsel Before Important September 12 Deadline in Securities Class Action - BHVN

Newsfile September 12, 2025

Contact Levi & Korsinsky by September 12, 2025 Deadline to Join Class Action Against Biohaven Ltd. (BHVN)

TheNewsWire September 12, 2025
View More News ››

Opinion & Analysis (NYSE:BHVN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSE:BHVN)

Be the first to post on this bullboard.

Freegold Ventures Limited

Freegold Ventures Limited

Freegold Ventures Limited is a Canada-based company focused on exploration in Alaska. The Company holds the Summit Gold ...
View More »

Podcasts